Key Points:

- Focused on the recent FDA approval of tarlatamab, a groundbreaking bispecific antibody in extensive stage SCLC
- DeLLphi-301 study, a phase two trial that demonstrated 40% objective response rate and a median overall survival of 14.3 months
- The operational challenges associated with its use, particularly the management of side effects like cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS)
In this episode of the Oncology Brothers podcast, we had the pleasure of discussing a significant advancement in the treatment of extensive stage small cell lung cancer with Dr. Misty Shields from Indiana University. We focused on the recent FDA approval of tarlatamab, a groundbreaking bispecific antibody that targets DLL3 and CD3 T cells, marking a pivotal moment in the management of this challenging disease.
Dr. Shields provided an in-depth overview of the DeLLphi-301 study, a phase two trial that demonstrated promising results, including a 40% objective response rate and a median overall survival of 14.3 months for patients treated with tarlatamab. We explored the study's design, the drug's mechanism of action, and the operational challenges associated with its use, particularly the management of side effects like cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS).
As community oncologists, we discussed the importance of collaboration between tertiary care centers and community practices to ensure patient safety and effective management of these side effects. Dr. Shields emphasized the need for a multidisciplinary approach and the establishment of standard operating procedures to monitor patients closely during treatment.
We also touched on the sequencing of tarlatamab with other therapies, such as lurbinectedin, and the potential for its use in high-grade neuroendocrine tumors, highlighting the evolving landscape of treatment options for patients with small cell lung cancer.
Finally, Dr. Shields shared information about the Longevity Small Cell Smashers, a patient advocacy group dedicated to supporting individuals diagnosed with small cell lung cancer. We encourage our listeners to engage with this community for education and support.
Thank you for joining us in this enlightening discussion. We look forward to bringing you more insights on recent approvals and practice-changing data in oncology. Stay tuned for our next episode!